
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Supplements and Featured Publications
almost 24 years ago
Participating Facultyalmost 24 years ago
Quality-of-Life Measurements: A Soft Outcome - Or is it?almost 24 years ago
Continuing Medical Education Quiz





